E
Elżbieta Bylina
Researcher at Curie Institute
Publications - 31
Citations - 990
Elżbieta Bylina is an academic researcher from Curie Institute. The author has contributed to research in topics: GiST & Sunitinib. The author has an hindex of 11, co-authored 28 publications receiving 808 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Piotr Rutkowski,Alessandro Gronchi,Peter Hohenberger,Sylvie Bonvalot,Patrick Schöffski,Sebastian Bauer,Elena Fumagalli,Paweł Nyckowski,Buu Phuc Nguyen,J.M. Kerst,Marco Fiore,Elżbieta Bylina,Mathias Hoiczyk,Annemieke Cats,Paolo G. Casali,Axel Le Cesne,Jürgen Treckmann,Eberhard Stoeckle,Johannes H. W. de Wilt,Stefan Sleijfer,R. Tielen,Winette T. A. van der Graaf,Cornelis Verhoef,Frits van Coevorden +23 more
TL;DR: The authors' analysis comprising the largest group of GIST patients treated with neoadjuvant imatinib in routine practice indicates excellent long-term results of combined therapy in locally advanced GISTs.
Journal ArticleDOI
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes
Piotr Rutkowski,Elżbieta Bylina,Agnieszka Wozniak,Zbigniew Nowecki,Czesław Osuch,Maciej Matłok,Tomasz Switaj,Wanda Michej,M Wronski,Stanisław Głuszek,J. Kroc,Anna Nasierowska-Guttmejer,Heikki Joensuu +12 more
TL;DR: The Joensuu criteria, which include 4 prognostic factors (tumour size, site, mitotic count and rupture) and 3 categories for the mitoticcount, were found to be a reliable tool for assessing prognosis of operable GIST.
Journal ArticleDOI
Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience
Agnieszka Wozniak,Agnieszka Wozniak,Piotr Rutkowski,Anna M. Piskorz,M. Ciwoniuk,Czesław Osuch,Elżbieta Bylina,Jacek Sygut,Maria Chosia,J. Rys,Katarzyna Urbańczyk,Wiesław Janusz Kruszewski,P. Sowa,Janusz A. Siedlecki,Maria Debiec-Rychter,Janusz Limon +15 more
TL;DR: KIT/PDGFRA mutational status has prognostic significance for patients' outcome and may help in management of patients with GISTs.
Journal ArticleDOI
Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.
Agnieszka Wozniak,Piotr Rutkowski,Patrick Schöffski,Isabelle Ray-Coquard,Isabelle Hostein,Hans-Ulrich Schildhaus,Axel Le Cesne,Elżbieta Bylina,Janusz Limon,Jean-Yves Blay,Janusz A. Siedlecki,Eva Wardelmann,Raf Sciot,Jean-Michel Coindre,Maria Debiec-Rychter +14 more
TL;DR: Tumor genotype is an independent molecular prognostic variable associated with gastric GIST and should be used for optimizing tailored adjuvant imatinib treatment, and presented remarkably superior 5-year DFS.
Journal ArticleDOI
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Piotr Rutkowski,Elżbieta Bylina,Anna Klimczak,Tomasz Świtaj,Sławomir Falkowski,J. Kroc,Iwona Ługowska,Magdalena Brzeskwiniewicz,Wojciech Melerowicz,Czesław Osuch,Ewa Mierzejewska,Kacper Wasielewski,Agnieszka Woźniak,Urszula Grzesiakowska,Zbigniew Nowecki,Janusz A. Siedlecki,Janusz Limon +16 more
TL;DR: It is confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year, and primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two independent factors influencing both PFS and OS.